ClinicalTrials.gg
CompletedNCT03777436DISCREETUpdated May 14, 2024Results posted

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

A Phase 3 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 52 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
289
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
9th of 44
289 · median 103
Started
2019
with 5 others
Phase 3
18 of 44
none open now
Registered
29th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 9th largest by enrollment, is one of 6 that started in 2019, is one of 18 in phase 3, and was the 29th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G ≥3, moderate or severe).

Approximately 286 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

Read the detailed description

The study will consist of four phases:

  • Screening Phase - up to 35 days
  • Double-blind Placebo-controlled Phase - Weeks 0 to 16

    • Subjects will be randomly assigned to either apremilast 30 mg tablets orally BID or placebo tablets (identical in appearance to apremilast 30 mg tablets) orally BID.
  • Apremilast Extension Phase - Weeks 16 to 32

    • All subjects will be switched to (or continue with) apremilast 30 mg BID. All subjects will maintain this dosing through Week 32.
  • Observational Follow-up Phase - 4 weeks - Four-week Post-Treatment Observational Follow-up Phase for all subjects who complete the study or discontinue the study early.
03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Genital Psoriasis
  • CC-10004
  • Apremilast
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 18 years of age at the time of signing the form (ICF).
  2. Subject must have a diagnosis of chronic plaque psoriasis for at least 6 months prior to signing the ICF.
  3. Subject must have a diagnosis of moderate or severe psoriasis of the genital area at Screening and Baseline.
  4. Subject must have a diagnosis of moderate or severe psoriasis at Screening and Baseline.
  5. Subject must have plaque psoriasis (BSA ≥ 1%) in a non-genital area at both Screening and Baseline.
  6. Subject must have been inadequately controlled with or intolerant of topical therapy, or topical therapy is inappropriate for the treatment of psoriasis affecting the genital area.
  7. Subject must be in good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.
  8. Subject must meet laboratory criteria

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has any significant medical condition or laboratory abnormality, that would prevent the subject from participating in the study.
  2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Subject has positive surface antigen or anti- antibody at Screening.
  4. Subject has active tuberculosis (TB) or a history of incompletely treated TB.
  5. Subject has prior history of suicide attempt at any time in the subject's life time prior to signing the and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
  6. Subject has current or planned therapies that may have a possible effect on psoriasis of the body and/or genital area during the course of the treatment phase of the trial
  7. Subject had prior treatment with apremilast.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    Arm A- Apremilast with Placebo

    Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks

    Drug: Apremilast · Other: Placebo

  • Experimental
    Arm B - Apremilast 30 mg

    All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study

    Drug: Apremilast

Interventions

  • Oral

    Also known as: CC-10004, Otezla

  • OtherPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Modified sPGA-G Response at Week 16

    The modified sPGA-G is the assessment by the Investigator of the participant's psoriasis lesions' overall disease severity in the genital area at the time of evaluation. The modified sPGA-G is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, plaque elevation, and scaling. A modified sPGA-G response is defined as modified sPGA-G score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the multiple imputation (MI) method. Two-sided 95% confidence intervals (CIs) for the within-group proportions were based on the Wilson-score method.

    Time frame: Baseline and Week 16 of the Placebo-controlled Phase

Secondary outcomes

  1. Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16

    The sPGA is the assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 3 (moderate) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  2. Percentage of Participants With a Genital Psoriasis Itch Numeric Rating Scale (GPI-NRS) Response at Week 16

    The GPI-NRS is a self-reported measure where participants were asked to assess their psoriasis symptoms in the genital area and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A GPI-NRS response is defined as ≥ 4 point reduction (improvement) from Baseline. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  3. Change From Baseline in Affected Body Surface Area (BSA) at Week 16

    The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total BSA). A negative change from Baseline indicates a reduction of affected BSA. Based on mixed-effect model for repeated measures (MMRM) model.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  4. Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0-30, where 0 represents the best score, and 30 represents the worst health-related quality of life. A negative change from Baseline indicates an improvement in health-related quality of life scores.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  5. Change From Baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16

    The GPSS is a self-reported measure where participants were asked to assess each of their psoriasis symptoms (itch, pain, discomfort, stinging, burning, redness, scaling, and cracking) in the genital area and select a number on a scale of 0-10, where 0 represents no symptoms, and 10 represents the worst imaginable. Results from each symptom assessment were summed to generate a total GPSS score ranging from 0 (no genital psoriasis symptoms) to 80 (worst imaginable genital psoriasis symptoms). A negative change from Baseline indicates an improvement in genital psoriasis symptoms.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

07

Results

Posted Dec 15, 2022

Participant flow

Participants were enrolled at 49 centers in Belgium, Canada, France, Germany, Italy, and the United States from February 2019 to February 2022.

Placebo-controlled Phase
Participant flow — Placebo-controlled Phase
MilestonePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast Extension Phase: Apremilast 30 mg
Started1461430
Took at least 1 dose of investigational product (ip)1451430
Completed1111190
Not completed35240
Withdrew: Adverse event8100
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject1930
Withdrew: Non-compliance with study drug020
Withdrew: Lost to follow-up770
Withdrew: Physician decision010
Withdrew: Due to covid-19 control measures100
Apremilast Extension Phase
Participant flow — Apremilast Extension Phase
MilestonePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast Extension Phase: Apremilast 30 mg
Started00229
Took at least 1 dose of ip00228
Completed00201
Not completed0028
Withdrew: Adverse event006
Withdrew: Lack of efficacy001
Withdrew: Withdrawal by subject0013
Withdrew: Lost to follow-up007
Withdrew: Miscellaneous001

Outcome measures

PrimaryPercentage of Participants With a Modified sPGA-G Response at Week 16

The modified sPGA-G is the assessment by the Investigator of the participant's psoriasis lesions' overall disease severity in the genital area at the time of evaluation. The modified sPGA-G is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, plaque elevation, and scaling. A modified sPGA-G response is defined as modified sPGA-G score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the multiple imputation (MI) method. Two-sided 95% confidence intervals (CIs) for the within-group proportions were based on the Wilson-score method.

Time frame:
Baseline and Week 16 of the Placebo-controlled Phase
Reported as:
Number · Percentage of participants
Percentage of Participants With a Modified sPGA-G Response at Week 16
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a Modified sPGA-G Response at Week 1619.5 (12.7 to 26.3)39.6 (31.2 to 48.0)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0003 · Adjusted difference: 20.1 · 95% CI 9.2 to 30.9Adjusted difference is the weighted average of the treatment differences across the strata with the Cochran-Mantel-Haenszel (CMH) weights. 2-sided 95% CIs based on the stratified Newcombe method. Two-sided p-values were based on the CMH test.
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16

The sPGA is the assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 3 (moderate) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 166.9 (2.7 to 11.2)22.2 (15.0 to 29.3)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0004 · Adjusted difference: 15.2 · 95% CI 6.9 to 23.6Adjusted difference is the weighted average of the treatment differences across the strata with the CMH weights. 2-sided 95% CIs based on the stratified Newcombe method. Two-sided p-values were based on the CMH test.
SecondaryPercentage of Participants With a Genital Psoriasis Itch Numeric Rating Scale (GPI-NRS) Response at Week 16

The GPI-NRS is a self-reported measure where participants were asked to assess their psoriasis symptoms in the genital area and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A GPI-NRS response is defined as ≥ 4 point reduction (improvement) from Baseline. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants With a Genital Psoriasis Itch Numeric Rating Scale (GPI-NRS) Response at Week 16
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a Genital Psoriasis Itch Numeric Rating Scale (GPI-NRS) Response at Week 1619.6 (11.9 to 27.4)47.3 (37.9 to 56.6)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 27.4 · 95% CI 15.4 to 39.3Adjusted difference is the weighted average of the treatment differences across the strata with the CMH weights. 2-sided 95% CIs based on the stratified Newcombe method. Two-sided p-values were based on the CMH test.
SecondaryChange From Baseline in Affected Body Surface Area (BSA) at Week 16

The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total BSA). A negative change from Baseline indicates a reduction of affected BSA. Based on mixed-effect model for repeated measures (MMRM) model.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Least squares mean · Change in percentage of affected BSA
Change From Baseline in Affected Body Surface Area (BSA) at Week 16
Change in percentage of affected BSAPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Affected Body Surface Area (BSA) at Week 16-0.79 ± 0.669-4.12 ± 0.664
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · MMRM · p = 0.0005 · Least squares mean difference: -3.33 · 95% CI -5.18 to -1.47Based on MMRM model.
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0-30, where 0 represents the best score, and 30 represents the worst health-related quality of life. A negative change from Baseline indicates an improvement in health-related quality of life scores.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
Scores on a scalePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16-2.6 ± 0.57-5.3 ± 0.55
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · MMRM · p = 0.0008 · Least squares mean difference: -2.7 · 95% CI -4.2 to -1.1Based on MMRM model.
SecondaryChange From Baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16

The GPSS is a self-reported measure where participants were asked to assess each of their psoriasis symptoms (itch, pain, discomfort, stinging, burning, redness, scaling, and cracking) in the genital area and select a number on a scale of 0-10, where 0 represents no symptoms, and 10 represents the worst imaginable. Results from each symptom assessment were summed to generate a total GPSS score ranging from 0 (no genital psoriasis symptoms) to 80 (worst imaginable genital psoriasis symptoms). A negative change from Baseline indicates an improvement in genital psoriasis symptoms.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16
Score on a scalePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16-5.3 ± 1.85-20.5 ± 1.83
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · MMRM · p = <0.0001 · Difference: -15.1 · 95% CI -20.3 to -10.0Based on MMRM model.

Adverse events

Collected over Up to a maximum of 41.4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Phase: Placebo0/145 (0%)2/145 (1.4%)39/145 (26.9%)
Placebo-controlled Phase: Apremilast 30 mg0/143 (0%)3/143 (2.1%)73/143 (51%)
Apremilast Extension Phase: Apremilast 30 mg0/229 (0%)2/229 (0.9%)53/229 (23.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast Extension Phase: Apremilast 30 mg
Herpes zosterInfections and infestations0/1451/1430/229
Clavicle fractureInjury, poisoning and procedural complications0/1451/1430/229
PsoriasisSkin and subcutaneous tissue disorders0/1451/1430/229
Clostridium difficile infectionInfections and infestations1/1450/1430/229
GastroenteritisInfections and infestations1/1450/1430/229
Urinary tract infectionInfections and infestations1/1450/1430/229
Ankle fractureInjury, poisoning and procedural complications1/1450/1430/229
DehydrationMetabolism and nutrition disorders1/1450/1430/229
AppendicitisInfections and infestations0/1450/1431/229
Actinic keratosisSkin and subcutaneous tissue disorders0/1450/1431/229
Most frequent other events
Most frequent other events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremilast Extension Phase: Apremilast 30 mg
DiarrhoeaGastrointestinal disorders12/14537/14327/229
HeadacheNervous system disorders16/14533/14315/229
NauseaGastrointestinal disorders11/14532/14317/229
NasopharyngitisInfections and infestations12/14512/14311/229

Baseline characteristics

The intent-to-treat (ITT) analysis set consisted of all participants who are randomized regardless of whether the participant received investigational product (IP).

Age, Continuous
Age, Continuous(Years)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Mean46.4 ± 14.3843.5 ± 13.3645.0 ± 13.93
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Female444387
Male102100202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Hispanic or Latino131831
Not Hispanic or Latino131125256
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
American Indian or Alaska Native000
Asian8412
Native Hawaiian or Other Pacific Islander101
Black or African American369
White131131262
More than one race000
Unknown or Not Reported325
Modified Static Physician Global Assessment of Genitalia (sPGA-G) Score
Modified Static Physician Global Assessment of Genitalia (sPGA-G) Score(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
3 (Moderate)128123251
4 (Severe)182038
08

Study locations

52 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Glick Skin Institute
    Margate, Florida 33073, United States
  • International Dermatology Research, Inc
    Miami, Florida 33144, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Adult and Pediatric Dermatology
    Overland Park, Kansas 66211, United States
  • ActivMed Practices and Research Inc
    Beverly, Massachusetts 01915, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • J Woodson Dermatology and Associates
    Henderson, Nevada 89052, United States
  • Las Vegas Dermatology
    Las Vegas, Nevada 89144, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
  • ActivMed
    Portsmouth, New Hampshire 03801, United States
  • Stony Brook Dermatology Associates
    Stony Brook, New York 11790, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Oakview Dermatology
    Athens, Ohio 45701, United States
  • Ohio State University Medical Center
    Gahanna, Ohio 43230, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Paddington Testing Company Inc
    Philadelphia, Pennsylvania 19103, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Virginia Clinical Research Inc
    Norfolk, Virginia 23502, United States
  • Bellevue Dermatology Clinic
    Bellevue, Washington 98004, United States
  • Dermatology Center for Skin Health
    Morgantown, West Virginia 26505, United States
  • Centre Hospitalier Universitaire Saint Pierre
    Brussels, 1000, Belgium
  • Cliniques Universitaires St Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P1X2, Canada
  • K Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Dre Angelique Gagne-Henley M.D. Inc
    Saint-Jerome, Quebec J7Z 7E2, Canada
  • Skincare Studio
    St. John's, A1E 1V4, Canada
  • Hopital Claude Huriez CHRU Lille
    Lille, 59037, France
  • CHU de Nice Archet I
    Nice, 06202, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Saint-Andre
    Pessac, 33604, France
  • Larrey University Hospital
    Toulouse, 31000, France
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Universitaetsklinikum Bonn
    Bonn, 53127, Germany
  • Hautklinik Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitaetsklinikum Schleswig-Holstein, Campus Luebeck
    Luebeck, 23538, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55101, Germany
  • Ospedali Riuniti di Ancona
    Ancona, 60020, Italy
  • Presidio Ospedaliero della Misericordia
    Grosseto, 58100, Italy
  • Azienda Sanitaria Locale 1 Ospedale Regionale San Salvatore
    LAquila, 67100, Italy
  • Azienda Ospedaliera Di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera Bianchi Melacrino Morelli
    Reggio Calabria, 89124, Italy
  • Universita degli Studi di Roma La Sapienza Ospedale A Fiorini di Terracina
    Terracina, 04019, Italy
  • Azienda Sanitaria Universitaria Integrata di Trieste
    Trieste, 34125, Italy
  • GCM Medical Group, PSC
    San Juan, 00917, Puerto Rico
09

References and documents

Publications

  • Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024 Mar;90(3):485-493. doi: 10.1016/j.jaad.2023.10.020. Epub 2023 Oct 16. PubMed 37852306 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Sep 2021, 31 months.

Results were first posted in Dec 2022, 1 year 2 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 31 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2018
First posted
Dec 17, 2018
StartActual
Feb 11, 2019
Primary completionActual
Sep 23, 2021
CompletionActual
Feb 9, 2022
Results first posted
Dec 15, 2022
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03777436
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Feb 11, 2019
Primary completion
Sep 23, 2021
Completion
Feb 9, 2022
Results posted
Dec 15, 2022
Last update
May 14, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion